在癌症中的YAP,TAZ和Hippo-Dysregulating融合蛋白
Jordan H Driskill1,2, Josephine K Dermawan3,4, Cristina R Antonescu3
1Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
涉及YAP1或WWTR1的基因融合驱动癌症,是治疗目标. 本综述探讨了这些瘤蛋白,它们的机制和脆弱性,提供了一个预测瘤潜在的框架.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 基因融合是癌症的关键驱动因素,也是治疗的目标.
- YAP1 (YAP) 和WWTR1 (TAZ) 是转录协激活剂和Hippo通路的作用器.
- 河马通路的失调与各种癌症有关.
研究的目的:
- 审查与YAP/TAZ或Hippo通路基因融合相关的瘤.
- 阐明这些融合蛋白的致癌机制.
- 为了确定这些仿真基蛋白的潜在治疗漏洞.
主要方法:
- 在人类瘤中对YAP1,WWTR1和Hippo通路基因融合的文献综述.
- 分析由这些融合蛋白驱动的致癌机制.
- 开发一个预测框架,用于新型融合的致癌潜力.
主要成果:
- 在不同的人类瘤中发现了涉及YAP1和WWTR1的复发性基因融合.
- 这些融合驱动瘤发生的详细机制.
- 突出了YAP/TAZ融合蛋白的保存和独特的脆弱性.
结论:
- YAP/TAZ-和Hippo-dysregulating基因融合代表了一大类致癌驱动因素.
- 了解这些融合为多种癌症类型提供了治疗机会.
- 一个预测框架有助于识别新的致癌融合蛋白.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Ras Gene
Ras is a...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
